# US 2015/0148256 A1 · Bioluminescence imaging-based screening assay and inhibitors of abcg2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148256 A1
- Document ID: US20150148256A1
- Status: Published application
- Kind: A1
- Application number: 14/465,440
- Filed: 2014-08-21
- Published: 2015-05-28
- Earliest claimed: 2008-11-12
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: MARTIN GILBERT POMPER; YIMAO ZHANG; JOHN LATERRA
- Web page: https://patentgrep.com/patent/US20150148256A1

## CPC

- G01N 33/5041: {involving analysis of members of signalling pathways}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 36/752: Citrus, e.g. lime, orange or lemon
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61K 51/02: characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus}
- A61K 51/0453: {having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C12Q 1/66: involving luciferase
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described.

## Claims

### Claim 1

A method for identifying inhibitors of ABCG2 comprising imaging at least one culture comprising a test compound, luciferin and cells that express ABCG2 and firefly luciferase; and selecting a test compound resulting in at least two-fold bioluminescence signal enchancement as an ABCG2 inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the culture is prepared by adding test compound to a culture comprising cells that express ABCG2 and firefly luciferase.

### Claim 3 (depends on 1)

The method of claim 1, further comprising imaging cultures comprising different concentrations of the same test compound.

### Claim 4 (depends on 1)

The method of claim 1, further comprising confirming the activity of the ABCG2 inhibitor.

### Claim 5 (depends on 4)

The method of claim 4, wherein confirming the activity comprises a resensitization assay or a dye uptake assay.

### Claim 6 (depends on 1)

A composition comprising an ABCG2 inhibitor identified by the method of claim 1, a chemotherapeutic agent and a pharmaceutically acceptable carrier or excipient, wherein the ABCG2 inhibitor and the chemotherapeutic agent in combination are present in a therapeutically effective amount and the therapeutic effectiveness of the chemotherapeutic agent in the combination with the ABCG2 inhibitor is greater than the therapeutic effectiveness of the chemotherapeutic agent in the absence of the ABCG2 inhibitor.

### Claim 7 (depends on 1)

A composition comprising an ABCG2 inhibitor identified by the method of claim 1, a CNS active agent, and a pharmaceutically acceptable carrier or excipient, wherein the ABCG2 inhibitor and the CNS active agent are present in a therapeutically effective amount and the therapeutic effectiveness of the CNS active agent in combination with the ABCG2 inhibitor is greater than the therapeutic effectiveness of the CNS agent in the absence of the ABCG2 inhibitor.

### Claim 8 (depends on 1)

A method of treating a cellular proliferative disorder comprising administering to a patient in need of treatment an ABCG2 inhibitor identified by the method of claim 1, optionally together with an additional chemotherapeutic agent.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A method of treating a central nervous system disorder comprising administering to a patient in need of treatment an ABCG2 inhibitor identified by the method of claim 1 and a therapeutically effective amount of a CNS active agent.

### Claim 11 (depends on 1)

A method of treating a multiple drug resistant tumor comprising administering an ABCG2 inhibitor identified by the method of claim 1 and a therapeutically effective amount of a chemotherapeutic agent different from the ABCG2 inhibitor.

### Claim 12

A method of treating a cellular proliferative disorder comprising administering to a patient in need of treatment a therapeutic amount of a compound selected from the group consisting of the compounds of Tables 2-6, optionally together with a therapeutically effective amount of a chemotherapeutic agent different from the ABCG2 inhibitor.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the compound is selected from the group consisting of the compounds of table 2, but excluding the compounds of tables 3 and 5.

### Claim 14 (depends on 12)

A method according to claim 12, wherein the compound is selected from the group consisting of glafenine, tracazolate, calcimycin (A23187), doxazosin, verteporfin, flavoxate, Brij 30, quinacrine, grapefruit oil, dihydroergotamine, harmaline, clebopride, silver nitrate isorhamnetin, gramicidin A, clebopride, rotenone, clomiphene, aromatic cascara fluid extract, sildenafil, emodin, flubendazole, metyrapone (2-methyl-1,2-dipyridin-3-yl-propan-1-one), periciazine (propericiazine), isoreserpine, acepromazine, flutamide, podophyllum resin, gambogic acid, piperacetazine, digitoxin, acetophenazine maleate, eupatorin, estrone hemisuccinate, raloxifene hydrochloride, o-dianisidine, oligomycin and combinations thereof.

### Claim 15 (depends on 12)

A method according to claim 12, wherein the compound is selected from the group consisting of doxazosin, Clebopride, Rotenone, Flavoxate, Dihydroergotamine, Glafenine, Flutamide, Emodin, Clomiphene, Flubendazole, Raloxifene, Piperacetazine, Tracazolate, Estrone, Podophyllum resin, Harmaline, o-Dianisidine, Acetophenazine, Acepromazine, Metyrapone, propericyazine, and combinations thereof.

### Claim 16 (depends on 12)

A method according to claim 12, wherein the compound is selected from the group consisting of Doxazosin, flavoxate, dihydroergotamine, and combinations thereof.

### Claim at position 17

17-21. (canceled)

### Claim 22 (depends on 1)

A method of imaging cells, tumors, tissues or organs that express ABCG2 comprising administering an effective amount of an ABCG2 inhibitor identified by the method of claim 1, labeled with one or more radioisotopes.

### Claim 23

A method of imaging cells, tumors, tissues or organs that express ABCG2 comprising administering an effective amount of an ABCG2 inhibitor selected from the group consisting of the compounds listed in Tables 2-6, labeled with one or more radioisotopes.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

A method according to claim 23, wherein the compound is selected from the group consisting of glafenine, tracazolate, calcimycin (A23187), doxazosin, verteporfin, flavoxate, Brij 30, quinacrine, grapefruit oil, dihydroergotamine, harmaline, clebopride, silver nitrate isorhamnetin, gramicidin A, clebopride, rotenone, clomiphene, aromatic cascara fluid extract, sildenafil, emodin, flubendazole, metyrapone (2-methyl-1,2-dipyridin-3-yl-propan-1-one), periciazine (propericiazine), isoreserpine, acepromazine, flutamide, podophyllum resin, gambogic acid, piperacetazine, digitoxin, acetophenazine maleate, eupatorin, estrone hemisuccinate, raloxifene hydrochloride, o-dianisidine, oligomycin and combinations thereof.

### Claim 26 (depends on 23)

A method according to claim 23, wherein the compound is selected from the group consisting of doxazosin, Clebopride, Rotenone, Flavoxate, Dihydroergotamine, Glafenine, Flutamide, Emodin, Clomiphene, Flubendazole, Raloxifene, Piperacetazine, Tracazolate, Estrone, Podophyllum resin, Harmaline, o-Dianisidine, Acetophenazine, Acepromazine, Metyrapone, propericyazine, and combinations thereof.

### Claim 27 (depends on 23)

A method according to claim 23, wherein the compound is selected from the group consisting of Doxazosin, flavoxate, dihydroergotamine, and combinations thereof.
